Please login to the form below

Olumiant

This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.

Researchers use AI to identify drugs that could be repurposed for Alzheimer’s

Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing. ... One of the drugs identified using the DRIAD method was Eli Lilly’s Olumiant(baricitinib), which will be investigated in a clinical trial for patients with

Latest news

Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval

35%. Baricitinib is already marketed by Lilly as Olumiant, for the treatment of adults with moderate to severe rheumatoid arthritis in the US.
Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

inhibitor Olumiant (baricitinib) for the novel coronavirus.
Lilly seeks US emergency approval after posting new data for COVID-19 antibodies

In addition to its studies of the COVID-19 targeting antibodies, Lilly is also undertaking clinical development of its JAK inhibitor Olumiant (baricitinib) in combination with Gilead’s remdesivir in patients ... Lilly is also seeking an emergency use
Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

A study of Eli Lilly’s JAK inhibitor Olumiant in combination with Gilead’s antiviral med remdesivir met its primary endpoint in patients hospitalised with COVID-19. ... The ACTT-2 trial, which was sponsored by the US National Institute of Allergy and
AbbVie, Amgen and Takeda team up for joint COVID-19 trial

This includes remdesivir, and Gilead is planning combination studies of the antiviral drug when taken alongside Eli Lilly’s JAK inhibitor Olumiant (baricitinib) and Actemra.

More from news
Approximately 6 fully matching, plus 29 partially matching documents found.

Latest Intelligence

NICE – but not enough

Olumiant launched in 2017 and received positive recommendations from NICE and SMC in the middle of Q3 that same year. ... Today – more than three years after its NICE TA – Olumiant is finally approaching full implementation.
Drug launches to watch in 2019

Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
Live webinar: Navigating new frontiers: Ways to find space in the future RA market

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Content Editor - Biotechnology: Salary TBC

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Account Management: Competitive Salary Offered

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

How a design mindset can lead to better medical outcomes: By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...
How does the government plan to reshape the NHS?: Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
Want to give perfect client service? Tough luck, you’re human: In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...